In the latest trading session, Bellerophon Therapeutics (BLPH) closed at $0.69, marking a -1.78% move from the previous day. This move lagged the S&P 500's daily loss of 0.79%. Elsewhere, the Dow lost ...

Bellerophon Therapeutics (BLPH) closed at $10.04 in the latest trading session, marking a -0.4% move from the prior day. This change lagged the S&P 500's daily gain of 0.09%. Meanwhile, the Dow gained ...

Though its eponym in Greek mythology was able to successfully defeat the fire-breathing chimera, Bellerophon Therapeutics’ story is closing out on a much less victorious note. The New Jersey-based ...

Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States WARREN, N.J., July 13, 2020 (GLOBE ...

TARRYTOWN, N.Y. — As post-lunch drowsiness settled on an auditorium full of leaders from the drug development industry, Peter Fernandes, CEO of Bellerophon Therapeutics, seized the presentation ...

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is ...

In an important reminder that plugging digital tools into a clinical trial will not magically solve problems, Bellerophon Therapeutics announced Monday it would abandon a study of its treatment for ...

WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering ...

Entera Bio Ltd. (NASDAQ:ENTX), Orphazyme A/S (NASDAQ:ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) are among the biggest biopharma movers Wednesday. Entera Bio Climbs On Positive Data For ...